Sign In
Buy PCVX
$51.96
-0.150 (-0.288%)
At Close: Jun 23, 2026
Vaxcyte Reports Third Quarter 2024 Financial Results and Provides Business Update
04:01pm, Tuesday, 05'th Nov 2024
-- Company Reported Positive Topline Safety, Tolerability and Immunogenicity Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate, in Adults Aged 50 and Ol
Vaxcyte to Present at the 2024 Cantor Global Healthcare Conference
04:05pm, Wednesday, 11'th Sep 2024
SAN CARLOS, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
Vaxcyte's Broad-Spectrum Pneumococcal Vaccines Poised For Market Dominance By 2027
09:00am, Sunday, 08'th Sep 2024
Vaxcyte's XpressCF platform enables the development of broad-spectrum vaccines, overcoming the limitations of traditional cell-based approaches. VAX-31 and VAX-24 are Vaxcyte's key value drivers. They
SAN CARLOS, Calif., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
Vaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong Buy
03:07pm, Friday, 06'th Sep 2024
Vaxcyte's stock surged this week due to promising Phase 1/2 data for its VAX-31 vaccine, showing superior immune responses compared to Pfizer's Prevnar 20. VAX-31 targets 31 strains, covering over 95%
Vaxcyte's stock dips after biotech completes $1.42 billion stock offering
09:07am, Friday, 06'th Sep 2024
Vaxcyte Inc.'s stock fell 3% early Friday, after the company completed a stock offering that is expected to generate $1.42 billion in proceeds.
Vaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record high
01:22am, Thursday, 05'th Sep 2024
Vaxcyte , a clinical-stage vaccine developer, will raise $1.3 billion in gross proceeds by selling common stock and warrants, it said late on Wednesday, a day after its shares surged to a record high
Vaxcyte Announces Pricing of $1.3 Billion Public Offering
11:58pm, Wednesday, 04'th Sep 2024
SAN CARLOS, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results
11:56am, Wednesday, 04'th Sep 2024
Data from an early-stage study shows that PCVX's pneumococcal vaccine has achieved immune responses rivaling vaccines marketed by Pfizer and Merck.
Vaxcyte Announces Commencement of Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:01pm, Tuesday, 03'rd Sep 2024
SAN CARLOS, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the conseq
Vaxcyte's Drug Update Pushes 2 Biotech Stocks Lower
02:10pm, Tuesday, 03'rd Sep 2024
Vaxcyte Inc (NASDAQ:PCVX) stock is surging today, after the biotechnology company announced positive study results for its drug designed to prevent invasive pneumococcal disease in adults aged 50 or o
Look Out, Pfizer and Merck. Vaxcyte Posts Strong Pneumococcal Vaccine Data.
10:48am, Tuesday, 03'rd Sep 2024
At the highest dose tested, Vaxcyte's shot elicited a stronger immune response against 18 of the 20 strains compared with Pfizer's.
Vaxcyte's shares jump on 'promising' early data on pneumococcal vaccine
09:24am, Tuesday, 03'rd Sep 2024
Vaxcyte's shares surged more than 30% on Tuesday after the vaccine developer said its experimental pneumococcal vaccine showed promising results in an early-stage study, with a safety profile similar
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
09:07am, Tuesday, 03'rd Sep 2024
Vaxcyte shares rocketed Tuesday after the biotech company delivered "stunning" test results for its pneumococcal vaccine.
Vaxcyte's stock soars 33% after trial shows positive data for pneumococcal vaccine
08:51am, Tuesday, 03'rd Sep 2024
Vaxcyte Inc.'s stock soared 33% early Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 a
